Platelets have a key role in atherogenesis and its complications. Both hypercholesterolemia and increased platelet production promote atherothrombosis; however, a potential link between altered cholesterol homeostasis and platelet production has not been explored. Here we show that transplantation of bone marrow deficient in ABCG4, a transporter of unknown function, into Ldlr −/− mice resulted in thrombocytosis, accelerated thrombosis and atherosclerosis. Although not detected in atherosclerotic lesions, Abcg4 was highly expressed in bone marrow megakaryocyte progenitors (MkPs). Abcg4 −/− MkPs had defective cholesterol efflux to high-density lipoprotein (HDL), increased cell surface expression of the thrombopoietin (TPO) receptor (c-MPL) and enhanced proliferation. These consequences of ABCG4 deficiency seemed to reflect disruption of negative feedback regulation of c-MPL signaling by the E3 ligase c-CBL and the cholesterol-sensing LYN kinase. HDL infusion reduced platelet counts in Ldlr −/− mice and in a mouse model of myeloproliferative neoplasm in an ABCG4-dependent fashion. HDL infusions may offer a new approach to reducing atherothrombotic events associated with increased platelet production. npg
Atherothrombotic events resulting in heart attack and stroke are the leading cause of morbidity and mortality globally 1 . Platelets are involved in multiple steps leading to atherothrombosis, both in the promotion of atherosclerotic plaque growth and also in the formation of thrombi on ruptured or eroded plaques [2] [3] [4] [5] . Increased numbers and activation of platelets both contribute to atherothrombotic risk 6, 7 , and increased platelet production may underlie these processes 6, 8 . A striking example of increased platelet production occurs in myeloproliferative neoplasms such as myelofibrosis and essential thrombocytosis, in which mutations in the gene encoding c-MPL or in the genes encoding its downstream signaling elements lead to excessive production of megakaryocytes and thrombocytosis 9 . More generally, increased platelet production, denoted by increased platelet volume and increased numbers of circulating reticulated platelets, is a major risk factor for atherosclerotic cardiovascular disease and may precipitate acute coronary syndromes 6 .
Increased amounts of low-density lipoprotein and decreased amounts of HDL are also well known major risk factors for atherothrombosis 10 . The atheroprotective functions of HDL are thought to be mediated by its ability to promote cholesterol efflux from cells in the arterial wall in a process that is facilitated by the ATP-binding cassette transporters ABCA1 and ABCG1 (ref. 11) . Although hypercholesterolemia has been associated with increased platelet production, the underlying mechanisms are unclear 12 . Moreover, potential mechanisms linking defective cholesterol efflux pathways to platelet production have not been explored.
The ATP-binding cassette transporter ABCG4, which is highly homologous to ABCG1, promotes cholesterol efflux to HDL when overexpressed in cultured cells 13, 14 . However, ABCG4 is not expressed in macrophage foam cells, and its in vivo function and potential effects on atherogenesis remain unknown. Abcg4 expression has been detected in the brain and hematopoietic tissues such as fetal liver and bone marrow 15, 16 . To uncover how ABCG4 might act in the hematopoietic system, we assessed the effects of ABCG4 deficiency on hematopoietic function and atherogenesis in a hypercholesterolemic mouse model of atherosclerosis.
RESULTS

ABCG4 deficiency accelerates atherosclerosis and thrombosis
We assessed hematopoietic parameters and atherogenesis in a hypercholesterolemic mouse model of atherosclerosis by reconstituting irradiated Ldlr −/− mice with bone marrow from wild-type (WT) or Abcg4 −/− mice. We also performed atherosclerosis studies in Ldlr −/− mice transplanted with Abcg1 −/− bone marrow. After the mice had been fed a high-fat, high-cholesterol diet (WTD) for 12 weeks, atherosclerotic lesion size was significantly increased in the aorta of Ldlr −/− mice receiving bone marrow transplantation (BMT) with ABCG4-deficient bone marrow (Fig. 1a) . In contrast, mice receiving ABCG1-deficient bone marrow did not show increased advanced atherosclerosis ( Fig. 1a) , consistent with previous studies 17, 18 . Histological analysis of the lesions showed typical, macrophage foam cell-rich atherosclerotic lesions with no differences in morphology between the BMT groups (Supplementary Fig. 1a) . The Abcg4 knockout mice used were generated using a lacZ knock-in allele at the Abcg4 locus 14 . However, we found no lacZ-positive cells in lesions of mice receiving Abcg4 −/− bone marrow (Fig. 1b) . As a positive control, we stained aortic lesions from Ldlr −/− mice receiving Abca1 −/− Abcg1 −/− bone marrow (also generated with a lacZ knock-in allele in the Abcg1 locus) 19 and found lacZ-positive cells indicating Abcg1 expression in the lesions. Plasma lipid and lipoprotein concentrations were similar in recipients of WT or Abcg4 −/− bone marrow ( Supplementary  Fig. 1b-d) , as were leukocyte, monocyte ( Supplementary Fig. 1e,f) , total lymphocyte, B cell and T cell counts (data not shown). Platelet counts were 52% greater in Abcg4 −/− bone marrow recipients compared with recipients of WT bone marrow ( Fig. 1c) . We observed mild anemia and reticulocytosis in the Ldlr −/− mice receiving Abcg4 −/− bone marrow ( Supplementary Fig. 1g,h) .
Activated platelets contribute directly to atherogenesis 4 , in part by promoting activation and adhesion of monocytes to the arterial endothelium 3, 4 . The numbers of platelet-neutrophil and platelet-Ly6-C hi monocyte aggregates were increased in hypercholesterolemic mice receiving Abcg4 −/− bone marrow compared to those receiving WT bone marrow ( Supplementary Fig. 1i ). These aggregated leukocytes from the recipients of Abcg4 −/− bone marrow expressed higher levels of CD11b (as determined by mean fluorescence intensity (MFI)), a key cell adhesion molecule that facilitates adhesion to the endothelium 20 (Fig. 1d) , indicating they were more activated than in the WT bone marrow recipients. Depletion of platelets by injection of CD41-specific antibodies, which markedly reduced platelet count in Ldlr −/− mice receiving WT or Abcg4 −/− bone marrow (data not shown), reduced aggregate numbers and leukocyte CD11b expression ( Fig. 1d and Supplementary Fig. 1i ). Platelet microparticles promote atherogenesis by facilitating chemokine deposition onto the arterial endothelium and recruiting monocytes to lesions 21 . The numbers of platelet-derived microparticles were threefold higher in hypercholesterolemic mice receiving Abcg4 −/− bone marrow than in those receiving WT bone marrow ( Fig. 1e) . Circulating amounts of reticulated platelets correlate directly with platelet reactivity 22 and are strongly associated with increased risk of myocardial infarction in humans 23 . There was also a significant increase in the percentage of reticulated platelets in mice receiving Abcg4 −/− bone marrow ( Fig. 1f) , consistent with increased platelet production and turnover 24 . These findings are consistent with previous studies in which infusions of activated platelets increased atherosclerotic lesion formation 4 and suggest that increased endogenous platelet production in recipients of Abcg4 −/− bone marrow leads to accelerated atherogenesis.
Thrombocytosis and increased amounts of reticulated platelets would also be expected to promote thrombosis. Mice are resistant to spontaneous thrombosis on atherosclerotic plaques. Thus, to assess thrombogenicity, we evaluated thrombus formation in whole blood using an ex vivo perfusion chamber model. Compared to WT controls, we found a marked increase in Abcg4 −/− platelet adhesion and aggregation to a collagen-coated surface under shear-flow conditions ( Fig. 1g) . We also examined arterial thrombosis in vivo using a carotid artery thrombosis model. Carotid artery occlusion by a thrombus after injury with FeCl 3 was significantly accelerated in mice receiving Abcg4 −/− bone marrow compared to those receiving WT bone marrow ( Fig. 1h ). Together these findings indicate an increased propensity to thrombus formation in hypercholesterolemic mice with bone marrow ABCG4 deficiency.
ABCG4 is expressed in platelet progenitors
We first considered that ABCG4 might be acting in platelets to influence cholesterol efflux and platelet numbers. However, we did not detect Abcg4 mRNA in WT platelets or lacZ staining in platelets of Abcg4 −/− mice (data not shown). In Abcg4 −/− mice, there was no npg alteration in cholesterol efflux by platelets to HDL or in platelet cholesterol concentrations ( Supplementary Fig. 2a,b) , indicating that ABCG4 does not act in platelets to regulate circulating platelet numbers. Thus, the mechanisms by which ABCG4 acts to regulate platelet numbers seem to be distinct from those reported for the scavenger receptor SR-BI 25 .
The phenotype of ABCG4-deficient mice, including prominent thrombocytosis, mild anemia and increased numbers of reticulated platelets, platelet and leukocyte aggregates and platelet microparticles, resembles that of essential thrombocytosis 26 , a myeloproliferative neoplasm in which mutations in the genes encoding c-MPL or JAK2 in bone marrow progenitors lead to excessive proliferation of platelet progenitors and increased platelet production 9, 27 . Platelets are produced by megakaryocytes in the bone marrow and spleen, and megakaryocytes are derived from megarkaryocyte-erythrocyte progenitors (MEPs). We hypothesized that ABCG4 might be expressed in bone marrow platelet progenitors and could be involved in the regulation of their proliferation and in megakaryocytopoiesis. After separation of bone marrow hematopoietic cell populations by FACS ( Supplementary Fig. 3 ), we detected Abcg4 mRNA primarily in MEPs ( Fig. 2a) , with a lower level of expression in the common myeloid progenitor (CMP) population. We found very low or no Abcg4 expression in other cell types ( Fig. 2a) . The restricted expression of Abcg4 to MEPs contrasts with the expression of Abca1 and Abcg1, which are highly expressed in hematopoietic stem and progenitor cells (HSPCs) but not MEPs. To test whether Abcg4 is the main cholesterol efflux transporter expressed in MEPs, we treated mice with a liver X receptor (LXR) activator in the attempt to induce Abca1 and Abcg1 expression; however, there was little expression of these two genes in MEPs of the treated mice, suggesting that Abcg4 is the dominant transporter in these cells ( Supplementary Fig. 4a,b) .
Recent studies have shown that the MEP population contains CD41 + cells with megakaryocyte progenitor potential, as well as CD71 + cells with erythrocyte progenitor potential 28 . We further sorted the MEP population into CD41 + CD71 lo , CD41 lo CD71 + and CD41 lo CD71 lo cell populations ( Fig. 2b) and refer to CD41 + CD71 lo cells as MkPs. We found high Abcg4 expression in MkPs ( Fig. 2c ) and CD41 lo CD71 + cells (data not shown) and lower expression in CD41 lo CD71 lo cells ( Fig. 2c) . We then used immunofluorescence confocal microscopy to assess ABCG4 protein expression and localization in the MkPs. We detected specific ABCG4 staining in WT MkPs with ABCG4specific antibody but not in Abcg4 −/− MkPs or WT MkPs stained with npg isotype-matched control antibody ( Fig. 2d) . Notably, ABCG4 staining partially colocalized with Golgi and, particularly, trans-Golgi markers ( Fig. 2e) , whereas we detected no colocalization with c-MPL (plasma membrane), Lamp2 (lysosome) or calnexin (endoplasmic reticulum) ( Supplementary Fig. 5 and data not shown). Thus, ABCG4 is selectively expressed in the MEP and MkP populations and seems to localize partly to the trans Golgi.
ABCG4 deficiency increases MkP proliferation
The percentages of MkPs and CD41 lo CD71 lo MEPs, but not of HSPCs or CMPs, were significantly increased in the bone marrow of hypercholesterolemic recipients of Abcg4 −/− bone marrow compared to recipients of WT bone marrow (Fig. 2f) . The numbers of CD41 lo CD71 + erythrocyte progenitors were also increased in these mice (data not shown). mRNA levels of Gata1, PU.1 (also known as Sfpi1), Eklf (also known as Klf1) and Fli1, transcription factors known to have crucial roles in the regulation of MEP, MkP and erythrocyte progenitor cell proliferation and differentiation, were similar in Abcg4 −/− CD41 lo CD71 lo MEPs, CD41 + CD71 lo MkPs and CD41 lo CD71 + erythrocyte progenitors (data not shown), suggesting that the lineage choice of Abcg4 −/− hematopoietic cells is not markedly altered.
TPO is the most important growth factor regulating megakaryocyte and platelet lineage development in vivo 29 . We did not observe any change in plasma TPO concentrations in mice receiving Abcg4 −/− bone marrow compared to those receiving WT bone marrow ( Supplementary  Fig. 6a ). However, we found increased expression of c-MPL on the surface of Abcg4 −/− MkPs and CD41 lo CD71 lo MEPs (Fig. 2g ) but not on megakaryocytes or platelets (Supplementary Fig. 6b,c) . This is consistent with the expression profile of Abcg4 and the hypothesis that increased MkP proliferation is the underlying mechanism of thrombocytosis in ABCG4-deficient mice. Indeed, increased EdU incorporation into DNA was increased in MEPs from Abcg4 −/− mice compared to those from WT mice (Supplementary Fig. 6d ). Colony-formation assays showed a 2.5-fold increase in the number of megakaryocyte colonies arising from ABCG4-deficient compared to WT bone marrow in response to TPO (Fig. 2h) . Moreover, the number of megakaryocytes was increased in the bone marrow and spleen of Ldlr −/− mice receiving Abcg4 −/− bone marrow compared to those receiving WT bone marrow ( Supplementary Fig. 7a,b) .
Increased TPO-induced platelet production in Abcg4 −/− mice Platelet counts are tightly regulated by a negative feedback mechanism in which c-MPL at the surface of megakaryocytes and platelets serves as a clearance sink for TPO and thus limits the increase in platelet count that results from increased TPO-c-MPL signaling in bone marrow cells 29, 30 . TPO administration to mice may overwhelm the negative feedback regulatory mechanism, uncovering the effects of increased c-MPL activity 31 . To test the hypothesis that ABCG4 deficiency in MEPs and MkPs results in increased cell surface expression of c-MPL, increased sensitivity of cells to TPO and enhanced platelet production, we administered TPO to WT and Abcg4 −/− mice. The increase in the number of platelets was much more pronounced in Abcg4 −/− mice (2.1-fold) compared to WT mice (1.4-fold) ( Fig. 2i) . These results indicate that ABCG4 deficiency renders mice more responsive to TPO in vivo, consistent with the idea that increased c-MPL expression on MkPs is the mechanism underlying increased platelet production in Abcg4 −/− mice.
ABCG4 promotes cholesterol efflux from MkPs to HDL
We next investigated potential mechanisms linking ABCG4 deficiency to increased expression of c-MPL and increased proliferation and expansion of MkPs. We first examined cellular cholesterol efflux from WT and Abcg4 −/− MkPs using a fluorescent cholesterol analog (BODIPY-cholesterol)-based flow cytometry assay. ABCG4 deficiency was associated with reduced cholesterol efflux to reconstituted HDL (rHDL) in Abcg4 −/− MkPs (Fig. 3a) . BODIPY-cholesterol concentrations in Abcg4 −/− MkPs were also significantly increased (Fig. 3b) . These findings could indicate that ABCG4-deficiency resulted in defective cholesterol efflux or that membranes of Abcg4 −/− cells have a higher affinity, capacity or both for cholesterol. A substantial portion of the BODIPY-cholesterol that accumulated in Abcg4 −/− MkPs was in the plasma membrane ( Fig. 3c) . Free cholesterol content as assessed by filipin staining was also significantly increased in the plasma membrane of Abcg4 −/− MkPs (Fig. 3d) . Cholesterol accumulation is npg known to suppress the expression of cholesterol-responsive genes 32 . Accordingly, expression of the cholesterol-responsive genes Ldlr and Hmgcs1 was significantly (P < 0.05) decreased in Abcg4 −/− relative to the WT MEPs; however, this effect was not observed in granulocytemacrophage progenitors, which do not express Abcg4 ( Supplementary  Fig. 8a,b) . Thus, despite our findings showing that ABCG4 localizes to the Golgi (Fig. 2e) , ABCG4 deficiency results in defective cholesterol efflux to HDL and an increase in cell cholesterol content, including in the plasma membrane. These results are consistent with studies suggesting that sterol-rich plasma membrane lipid raft domains can be segregated from non-raft domains in the trans Golgi 33 .
To determine whether an increase in cellular cholesterol content can recapitulate the effects of ABCG4 deficiency, we loaded cells with cholesterol-cyclodextrin complexes. This led to increased proliferation of WT and Abcg4 −/− MkPs, paralleling increased cell surface c-MPL expression ( Fig. 3e,f) . After treatment of the cells with cyclodextrin to remove cellular cholesterol, proliferation and the cell surface expression of c-MPL in Abcg4 −/− MkPs were significantly reduced to levels similar to those in cyclodextrin-treated WT MkPs (Fig. 3e,f) . Although rHDL significantly reduced WT MkP proliferation and cell surface expression of c-MPL, it had no effect in Abcg4 −/− MkPs, consistent with the cholesterol efflux data (Fig. 3a) . In addition, removal of cellular cholesterol by cyclodextrin reversed the increase in the number of megakaryocyte colonies associated with ABCG4 deficiency (Supplementary Fig. 8c) . These findings suggest that ABCG4 acts to modulate MkP cell surface c-MPL expression and cell proliferation by regulation of membrane cholesterol content.
Decreased downregulation of TPO receptor in Abcg4 −/− MkPs We next studied mechanisms linking changes in cellular cholesterol concentrations to altered c-MPL expression in MkPs. Previous studies have shown that TPO binding to its receptor, c-MPL, results in activation of a negative feedback loop in which c-CBL-mediated ubiquitinylation leads to receptor internalization, degradation or both 34 . c-CBL phosphorylation in response to the activation of growth factor receptors is required to mediate negative feedback regulation 35 . We assessed whether such negative feedback regulation is defective in Abcg4 −/− MkPs. In response to TPO treatment, the increase in the amount of c-CBL tyrosine phosphorylation was markedly blunted in Abcg4 −/− compared to WT MkPs (Fig. 4a) , whereas the amount of total c-CBL was unchanged (data not shown). npg to a level similar to that in Abcg4 −/− cells (Fig. 4b) , consistent with the idea that in Abcg4 −/− there is decreased proteasomal degradation of c-MPL compared to WT cells. Cholesterol loading by cholesterol-cyclodextrin complexes reduced c-CBL phosphorylation, whereas removal of cellular cholesterol by cyclodextrin increased c-CBL phosphorylation in both WT and Abcg4 −/− MkPs (Fig. 4c) .
Although rHDL treatment increased the amount of phosphorylated c-CBL in WT MkPs, it did not alter c-CBL phosphorylation in Abcg4 −/− MkPs (Fig. 4c) , consistent with the inability of rHDL to modulate c-MPL expression and cell proliferation of Abcg4 −/− MkPs. These findings suggest that impaired cholesterol efflux in Abcg4 −/− MkPs results in defective c-CBL-mediated feedback downregulation of c-MPL by TPO.
LYN kinase modulates proliferative responses of MkPs
The kinase(s) catalyzing c-CBL tyrosine phosphorylation in response to TPO are not known. SRC-family kinases (SFKs) such as LYN, FYN and c-SRC are known to phosphorylate tyrosine residues of c-CBL 36 , leading to its activation, and SFK inhibitors have been shown to increase cell surface c-MPL expression through undefined mechanisms 29 . We hypothesized that the activity of SFKs is decreased in Abcg4 −/− MkPs, leading to decreased c-CBL phosphorylation. Consistent with this suggestion, treatment of WT and Abcg4 −/− MkPs with SU6656, an inhibitor of LYN, FYN and c-SRC 37 , markedly decreased c-CBL phosphorylation, increased cell surface expression of c-MPL and abolished the difference in response to TPO between WT and Abcg4 −/− MkPs (Fig. 4d,e) . TPO activation of c-MPL increases the kinase activity of LYN and FYN but not other SFKs 38 . LYN kinase is palmitoylated and membrane associated, and its activity is increased by decreased membrane cholesterol content 39 . Notably, Lyn −/− mice show increased megakaryocytopoiesis with mild thrombocytosis 40 and mild anemia with reticulocytosis 41 , defects that bear a striking resemblance to those of Abcg4 −/− mice. Thus we hypothesized that LYN might be the dominant tyrosine kinase catalyzing c-CBL tyrosine phosphorylation in response to TPO. TPO-treated Lyn −/− MkPs showed decreased c-CBL phosphorylation and increased cell surface c-MPL expression ( Fig. 4f,g) and cell proliferation compared to WT MkPs (Fig. 4h) , demonstrating that LYN has a key role in regulating the tyrosine phosphorylation of c-CBL and in MkP proliferation in response to TPO. Cholesterol loading by cholesterolcyclodextrin complexes decreased c-CBL phosphorylation, increased c-MPL expression and enhanced cell proliferation in WT MkPs but had no effect in Lyn −/− MkPs (Fig. 4f-h) . Treatments with either cyclodextrin or rHDL to induce cholesterol efflux decreased the proliferation of WT MkPs. In contrast, Lyn −/− MkPs showed increased proliferation that was unresponsive to either cholesterol loading or depletion treatments (Fig. 4h) . These findings indicate an essential role of LYN kinase in mediating the effects of cholesterol loading and unloading on c-CBL phosphorylation as well as the effects of TPO on c-MPL expression and MkP proliferation.
A LYN kinase activator reduces c-MPL expression
To further assess the possible involvement of LYN in the negative regulation of surface c-MPL expression on MkPs, we tested the effects of pharmacological LYN activation. Treatment of bone marrow cells from hypercholesterolemic Ldlr −/− recipient mice with tolimidone, a compound that selectively increases LYN kinase activity in vivo 42 , reduced cell surface c-MPL expression in both WT and Abcg4 −/− MkPs (Fig. 4i) and completely reversed the increased cell surface expression of c-MPL in Abcg4 −/− MkPs from normocholesterolemic mice (Supplementary Fig. 9 ). Together these observations suggest that in the presence of excessive membrane cholesterol accumulation, npg decreased LYN kinase activity leads to diminished c-CBL-mediated downregulation of c-MPL by TPO.
We assessed known TPO-mediated signaling pathways that could potentially be activated in Abcg4 −/− MkPs. Both basal and TPOstimulated amounts of phosphorylated ERK1/2 and phosphorylated Akt were significantly higher in Abcg4 −/− compared to WT MkPs; the amounts of phosphorylated STAT5 were also increased, albeit nonsignificantly (Fig. 4j) . This pattern is similar to that seen with LYN deficiency 40 .
HDL infusion decreases MkP proliferation and platelet count
To test whether HDL administration can reduce MkP proliferation and platelet counts in vivo, we infused a preparation of rHDL that has been shown previously to reduce coronary atheroma volume in humans 43 into WTD-fed Ldlr −/− mice with or without ABCG4 deficiency. rHDL, but not saline, infusion significantly decreased platelet counts by ~30% in Ldlr −/− but not Abcg4 −/− Ldlr −/− mice (Fig. 5a) . HDL infusion also caused decreased c-MPL expression on MkPs, decreased numbers and proliferation of MkPs and decreased megakaryocyte counts in spleen and bone marrow in Abcg4 +/+ mice; however, rHDL had no effect in Abcg4 −/− mice (Fig. 5b,c and Supplementary  Fig. 10a-c) . These findings demonstrate an essential role of ABCG4 in mediating the ability of rHDL to reduce MkP proliferation and platelet counts.
We further explored the therapeutic potential for rHDL to reduce platelet counts by testing the effects of rHDL infusion in a mouse model of myelofibrosis and essential thrombocytosis. In this model, mice are transplanted with bone marrow cells transduced with a retrovirus expressing an activating mutant form of c-MPL (c-MPL W515L ), found in human myeloproliferative neoplasms 27, 44 . Such c-MPL mutations are found in a subset of patients with myelofibrosis (~10%) and essential thrombocytosis (~4-5%) and cause proliferation of MEPs, megakaryocyte expansion and thrombocytosis 9, 27 . The activity of this mutant form of c-MPL requires cell surface localization 45 . Because cell surface c-MPL expression was increased in Abcg4 −/− mice (Fig. 2g) , we hypothesized that c-MPL activity might be enhanced by ABCG4 deficiency. Indeed, thrombocytosis developed more rapidly and was more pronounced in mice transplanted with Abcg4 −/− bone marrow cells with reteroviralmediated expression of c-MPL W515L compared to mice that received WT c-MPL W515L bone marrow cells (Fig. 5d) . Although rHDL infusions effectively reversed thrombocytosis in WT c-MPL W515L bone marrow-transplanted mice, the same treatment had no effect on platelet counts in mice transplanted with Abcg4 −/− c-MPL W515L bone marrow cells.
To test whether rHDL infusion in humans could reduce platelet numbers, we analyzed data obtained from a previously reported study involving patients with peripheral vascular disease 46 . This revealed that infusion of rHDL, but not placebo, was associated with a significant reduction of platelet counts (Fig. 5e) ; when normalized to baseline platelet values, the change was still significantly different between the groups (Fig. 5f) . The reduction of platelets in this study was moderate, and platelet counts were maintained in the normal range (Fig. 5e) .
Together these findings suggest that HDL and ABCG4 promote cholesterol efflux from MkPs and thus facilitate the negative feedback regulation of c-MPL by TPO in MkPs (Fig. 5g) .
DISCUSSION
Our findings show that defective cholesterol homeostasis in megakaryocyte progenitor cells promotes megakaryocyte formation, platelet overproduction, arterial thrombosis and atherogenesis. Increased membrane cholesterol concentrations in megakaryocyte progenitors lead to increased amounts and signaling of the TPO receptor. ABCG4 is highly expressed in MkPs, and its deficiency leads to cholesterol accumulation, MkP proliferation and increased platelet production. The ability of rHDL to suppress MEP and MkP proliferation and platelet counts in vivo was dependent on ABCG4, probably reflecting the cell type-restricted pattern of expression of cholesterol efflux-promoting ABC transporters. Therapeutic interventions such as rHDL infusions have the potential to reverse excessive megakaryocytopoiesis in states of platelet overproduction, such as those that occur in myeloproliferative neoplasms.
The idea that cellular sterol metabolism is intimately connected to proliferative responses is longstanding 47 . The requirement for new membrane synthesis during cell proliferation leads to activation of cholesterol biosynthesis involving cleavage of sterol regulatory element binding transcription factor 2 (SREBP-2) and transcriptional induction of cholesterol biosynthetic genes 48 . Recent studies have linked control of cell proliferation to cholesterol efflux pathways mediated by ABCA1, ABCG1 or both 19, [49] [50] [51] . However, specific molecular mechanisms linking cellular cholesterol accumulation to altered growth factor receptor signaling have not been defined. Our studies suggest that LYN kinase may act as a membrane cholesterol sensor, acting upstream of c-CBL to modulate its downregulation of c-MPL. This hypothesis is supported by previous studies showing that LYN kinase activity is modulated by altered membrane cholesterol concentrations 39 . LYN is palmitoylated, and palmitoylationdefective LYN shows decreased association with cholesterol-rich membranes but an increased ability to mediate tyrosine phosphorylation of immunoglobulin receptors 52 . We showed that infusions of cholesterol-poor rHDL were associated with a reduction in platelet counts in a previous small study involving patients undergoing treatment for peripheral vascular disease, suggesting the potential human relevance of our findings. Moreover, in a recent human genome-wide association study, SNPs in or near the c-CBL (also called CBL) gene were associated with platelet counts 53 . Interestingly, ABCG4 is in tight linkage disequilibrium with c-CBL, and SNPs associated with platelet counts could be influencing expression of c-CBL and/or ABCG4 (ref. 53) . Our findings suggest a potential mechanism linking expression of ABCG4 to the regulation of platelet counts involving defective c-CBL-mediated feedback regulation of c-MPL and thus support the concept that these genes act in megakaryocytes or their progenitors to regulate platelet production 53 .
There is tremendous interest in the development of new therapies that increase plasma HDL concentrations as potential treatments for atherosclerotic cardiovascular disease. The achievement of this goal has been challenging, as highlighted by the recent failure of treatments that increase HDL concentrations in clinical trials, such as the CETP inhibitors torcetrapib and dalcetrapib or extended release niacin 54, 55 . However, approaches that actively increase the flux of cholesterol from macrophages and other cells remain promising treatments to reduce coronary atherosclerosis 43, 56 . Our study suggests that such treatments may have the beneficial effects of suppressing MEP and MkP proliferation.
Thrombocytosis in essential thrombocytosis and myelofibrosis is currently treated with low-dose aspirin, and high-risk patients with essential thrombocytosis (>60 years old or having experienced a previous thrombotic event) are treated with genotoxic agents such as hydroxyurea 57 . There remains a need for new therapies for patients with myelofibrosis given their poor overall outcome and limited npg therapeutic options 58 . Our findings suggest that rHDL infusion may specifically reverse c-MPL-dependent MEP proliferation and aberrant megakaryopoiesis underlying thrombocytosis in essential thrombocytosis and myelofibrosis. Moreover, increased platelet production is a cardiovascular risk factor and has been implicated more generally in the precipitation of atherothrombotic events 6 . Thus, rHDL infusions could complement existing treatments that directly target platelets or clotting factors. rHDL infusions may have multiple beneficial effects in the setting of acute coronary syndromes, including the removal of cholesterol, the suppression of inflammation in plaques and the suppression of excessive myeloid cell production and extramedullary hematopoiesis, as well as limiting the overproduction of platelets 59, 60 . rHDL preparation and infusion as a chronic therapy remains challenging. Our findings showing that LYN kinase acts downstream of HDL to limit platelet production suggest that activators of LYN kinase may represent an alternative therapeutic approach.
METHODS
Methods and any associated references are available in the online version of the paper.
(KKVENHITEAQRFSHLPKR). Monospecific anti-peptide antibodies were purified using a peptide-affinity column. The specificity of the antibody for ABCG4 protein was assessed by immunofluorescence microscopy, which showed specific immunofluorescence signals in HEK293 cells expressing ABCG4 but not HEK293 cells transfected with mock vectors (data not shown).
Rabbit polyclonal antibody to c-MPL was kindly provided by W. Tong of the University of Pennsylvania, and the specificity of the antibody against cell surface c-MPL in flow cytometry has been reported previously 62, 63 .
Neutrophil and monocyte platelet aggregates. Blood was collected through the tail vein into EDTA-lined tubes on ice to prevent leukocyte activation. Red blood cells (RBCs) were lysed, and the washed cells were then stained with CD45 (Invitrogen), CD115 (eBioscience), Gr1 (Ly6-C/G; BD Biosciences), CD11b (eBioscience) and CD41 (eBioscience) at 1:200 dilution for 30 min on ice. The cells were carefully washed, resuspended in FACS buffer and run on an LSRII flow cytometer to detect leukocyte platelet interactions and leukocyte activation. Viable cells were selected on the basis of forward and side scatter characteristics, and then CD45 + leukocytes were selected. Ly6-C hi monocyte platelet aggregates were identified as CD115 + Gr1 hi (Ly6-C hi ) and CD41 + . Neutrophil-platelet aggregates were identified as CD115 − Gr1 + (Ly6-G + ) and CD41 + . Platelet-dependent activation of Ly6-C hi monocytes and neutrophils was measured as CD11b MFI after subtracting the expression of CD11b on Ly6-C hi or neutrophils, which stained negative for platelets (CD41 − ).
Platelet-derived microparticles. Equal amounts of mouse plasma (20 µl) were diluted with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) binding buffer (80 µl) and then incubated with annexin V (BD Biosciences, 556420) and antibody to CD41. Equal amounts of 1-µm beads (Invitrogen) were added to the sample as a size standard, which was then run on an LSRII flow cytometer. Platelet-derived microparticles were detected as particles less than 1 µm in size that stained positive for CD41 and annexin V. A standard amount of beads was acquired to ensure accurate counting in each sample. Data were converted to the number of microparticles per 1 µl of whole blood. Ex vivo flow chamber assay. Heparin (5 U ml −1 )-anticoagulated whole blood was incubated with 1 µM of the fluorescent dye DiOC6 (Sigma, St. Louis. Mo, USA) for 10 min at 37 °C. The fluorescently labeled whole blood was then perfused over a collagen-coated glass cover surface (microcapillary glass tube coated with 100 µm ml −1 Horm collagen (Nycomed) overnight) at a controlled shear rate (1,800 s −1 ) using a syringe pump for 3 min. Adherent platelets and aggregates in the chamber were washed and examined under an inverted fluorescent microscope, and micrographs of adhered platelets were recorded for analysis. Flow chamber surface coverage by the thrombi was calculated using ImageJ. c-MPL expression. After harvesting bone marrow progenitor cells, RBCs were lysed, and the cells were resuspended in FACS buffer. Bone marrow cells were stained for MkPs as stated above, and c-MPL or isotype control antibodies were included. Cells were then washed and stained with a fluorescently conjugated secondary rabbit-specific antibody to detect the antibody to c-MPL for a further 30 min on ice. Following this, the cells were washed, resuspended in FACS buffer and run on an LSRII flow cytometer. MEPs were identified as Lin − c-Kit + CD16/CD32 lo CD34 lo CD41 − , and MkPs were identified as Lin − c-Kit + CD16/CD32 lo CD34 lo CD41 + .
Expression of c-MPL on late-stage megakaryocytes was detected by staining bone marrow cells with a cocktail of lineage markers (Sca1, CD127, CD45R, CD19, CD3e, TER-119, CD2, CD8 and Ly6-C/G, all FITC conjugated; eBioscience), CD41 (eBioscience) and c-MPL or isotype control as above. After staining with the antibodies, the bone marrow cells were then fixed and permeabilized using BD cytofix/perm buffer for 20 min on ice followed by washing with BD cytofix/perm wash buffer. Cells were then resuspended in FACS buffer containing propidium iodide to determine megakaryocyte ploidy. Expression of c-MPL was measured on total and late-stage megakaryocytes (defined as 32N and 64N) .
Expression of c-MPL on platelets was assessed by obtaining platelet-rich plasma and staining with CD41 and c-MPL as outlined above. The surface expression of c-MPL on platelets was then quantified by MFI normalized to the isotype control. c-Cbl phosphorylation. Bone marrow progenitor cells were stimulated with TPO at the indicated concentration for the specified period of time at 37 °C and then immediately diluted with ice-cold buffer and placed on ice to prevent further changes in phosphorylation. Cells were then centrifuged at 800g for 2 min, and the pellet was resuspended in BD fix buffer (BD Biosciences) for 10 min on ice. The cells were washed with BD flow cytometry staining buffer, centrifuged and then resuspended in BD cytofix/perm buffer III for 20 min. After this, the cells were washed and resuspended in BD staining buffer and incubated with lineage (Sca1, CD127, CD45R, CD19, CD11b, CD3e, TER-119, CD2, CD8, CD4 and Ly-6G, all FITC; eBioscience) and progenitor cell markers (c-Kit, CD16/CD32 (FcγRII/III), CD34, CD41 and antibody to p-c-CBL (Tyr700 human, Tyr698 mouse; BD Biosciences)) or an isotype control for 30 min on ice. The cells were then washed, resuspended in FACS buffer and run on an LSRII. The amount of phosphorylated c-Cbl was normalized against that of isotype control staining.
Immunofluorescence confocal microscopy. MkPs collected by FACS from WT or Abcg4 −/− bone marrow cells were attached to glass slides by a brief spin in a CytoSpin4 (Thermo Scientific) according to the manufacturer's instructions. The cells were then fixed with 2% paraformaldehyde, permeabilized with 1% Triton X-100 in PBS for 1 min and incubated with 4% BSA in PBS plus 0.1% saponin to block nonspecific binding sites. Diluted primary antibodies against ABCG4 or cellular organelle markers (58K Golgi proteinspecific antibody, Novus Biologicals; TGN38-specific antibody, BD Biosciences; c-MPL-specific antibody, Sigma-Aldrich; Lamp2-specific antibody, Novus Biologicals) were then added to the cells in 1:200 dilution and incubated at room temperature for 2 h. After washing, fluorescent secondary antibodies (1:400 dilution) were added and incubated for 1 h. Where indicated, the washed cells were counterstained with or without DAPI and examined with a fluorescence confocal microscope.
Statistics.
For aortic morphometric atherosclerotic lesion quantification and analysis, two-way analysis of variance (ANOVA) was used. For comparison of one group with another, for instance in the c-CBL phosphorylation time course experiment (Fig. 4a) , a t test was used. For comparison of various treatments on different genotypes, one-way ANOVA was used.
